PRY2

Across TCGA pan-cancer cohorts, PRY2 RNA is linked to patient survival in 4 of 34 cancer types, making it the most broadly survival-associated PRY2 data layer.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher PRY2 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated PRY2 expression acts as an unfavorable survival marker.

ACC, PCPG, and ESCA are the cancer types where PRY2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	OS	Tertile	All	0.273	0.802	.017	45	view →
PCPG	OS	Tertile	All	0.723	0.975	.002	27	view →
ESCA	DFS	Tertile	III,IV	0.100	0.442	.003	27	view →
STAD	DFS	Tertile	II,III,IV	0.235	0.540	.044	9	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PRY2–ACC (OS)

Open the ACC breakdown →